Editing Diabetes (TRPM7)

{{tp|p=36717580|t=2023. Adipose-specific deletion of the cation channel TRPM7 inhibits TAK1 kinase-dependent inflammation and obesity in male mice.|pdf=|usr=}}{{36717580}}
{{tp|p=36574297|t=2023. TRPM7 kinase is required for insulin production and compensatory islet responses during obesity.|pdf=|usr=}}{{36574297}}
{{tp|p=34865947|t=2022. Associations between gene expression of magnesium transporters and glucose metabolism in pregnancy.|pdf=|usr=}}{{34865947}}
{{tp|p=34345920|t=2021. TRPM7 is a crucial regulator of pancreatic endocrine development and high-fat-diet-induced beta-cell proliferation.|pdf=|usr=}}{{34345920}}
{{tp|p=34072724|t=2021. The Combined Influence of Magnesium and Insulin on Central Metabolic Functions and Expression of Genes Involved in Magnesium Homeostasis of Cultured Bovine Adipocytes.|pdf=|usr=}}{{34072724}}
{{tp|p=33891828|t=2021. Leptin Induces Epigenetic Regulation of Transient Receptor Potential Melastatin 7 in Rat Adrenal Pheochromocytoma Cells.|pdf=|usr=}}{{33891828}}
{{tp|p=37837806|t=2023. Improvement of actin dynamics and cognitive impairment in diabetes through troxerutin-mediated downregulation of TRPM7/CaN/cofilin.|pdf=|usr=}}{{37837806}}
{{tp|p=31697634|t=2019. Leptin Activates Trpm7 Channels in the Carotid Body As a Mechanism of Obesity-Related Hypertension.|pdf=|usr=}}{{31697634}}
{{tp|p=27574117|t=2016. Intersection of calorie restriction and magnesium in the suppression of genome-destabilizing RNA-DNA hybrids.|pdf=|usr=}}{{27574117}}
{{tp|p=24057349|t=2014. Functional TRPV and TRPM channels in human preadipocytes.|pdf=|usr=}}{{24057349}}
{{tp|p=23765921|t=2014. TRPM7 channels regulate proliferation and adipogenesis in 3T3-L1 preadipocytes.|pdf=|usr=}}{{23765921}}
{{tp|p=20875900|t=2010. Gene variation of the transient receptor potential cation channel, subfamily M, members 6 (TRPM6) and 7 (TRPM7), and type 2 diabetes mellitus: a case-control study.|pdf=|usr=}}{{20875900}}
{{tp|p=19098369|t=2008. The role of transient receptor potential channels in metabolic syndrome.|pdf=|usr=}}{{19098369}}
{{tp|p=30742025|t=2019. Diabetes-induced hypomagnesemia is not modulated by metformin treatment in mice.|pdf=|usr=}}{{30742025}}
{{tp|p=34331987|t=2021. Fibrosis of the diabetic heart: Clinical significance, molecular mechanisms, and therapeutic opportunities.|pdf=|usr=}}{{34331987}}
{{tp|p=32393384|t=2020. Effect of long-term treatment of Carvacrol on glucose metabolism in Streptozotocin-induced diabetic mice.|pdf=|usr=}}{{32393384}}
{{tp|p=31604444|t=2019. Hypomagnesemia is associated with new-onset diabetes mellitus following heart transplantation.|pdf=|usr=}}{{31604444}}
{{tp|p=38186879|t=2024. Mechanisms and treatment of obesity-related hypertension-Part 1: Mechanisms.|pdf=|usr=}}{{38186879}}
{{ttp|p=36741996|t=2022. Effects of magnesium supplementation on improving hyperglycemia, hypercholesterolemia, and hypertension in type 2 diabetes: A pooled analysis of 24 randomized controlled trials.|pdf=|usr=}}{{36741996}}
{{tp|p=36346820|t=2023. Hypomagnesemia and Cardiovascular Risk in Type 2 Diabetes.|pdf=|usr=}}{{36346820}}
{{tp|p=35445032|t=2022. Dysregulated Erythroid Mg(2+) Efflux in Type 2 Diabetes.|pdf=|usr=}}{{35445032}}
{{tp|p=34277971|t=2021. Canagliflozin, serum magnesium and cardiovascular outcomes-Analysis from the CANVAS Program.|pdf=|usr=}}{{34277971}}
{{tp|p=33866775|t=2021. Lobeglitazone: A Novel Thiazolidinedione for the Management of Type 2 Diabetes Mellitus.|pdf=|usr=}}{{33866775}}
{{tp|p=33747462|t=2021. Association of dietary calcium, magnesium, and vitamin D with type 2 diabetes among US adults: National health and nutrition examination survey 2007-2014-A cross-sectional study.|pdf=|usr=}}{{33747462}}
{{tp|p=31196609|t=2019. Ion channels and transporters in diabetic kidney disease.|pdf=|usr=}}{{31196609}}
{{tp|p=28224192|t=2017. Serum magnesium and the risk of prediabetes: a population-based cohort study.|pdf=|usr=}}{{28224192}}
{{tp|p=28197834|t=2017. Effects of Canagliflozin on Serum Magnesium in Patients With Type 2 Diabetes Mellitus: A Post Hoc Analysis of Randomized Controlled Trials.|pdf=|usr=}}{{28197834}}
{{tp|p=33716794|t=2021. Vascular Dysfunction in Diabetes and Obesity: Focus on TRP Channels.|pdf=|usr=}}{{33716794}}
{{tp|p=31572181|t=2019. Carvacrol Attenuates Diabetic Cardiomyopathy by Modulating the PI3K/AKT/GLUT4 Pathway in Diabetic Mice.|pdf=|usr=}}{{31572181}}
{{tp|p=30889804|t=2019. Effects of Magnesium Deficiency on Mechanisms of Insulin Resistance in Type 2 Diabetes: Focusing on the Processes of Insulin Secretion and Signaling.|pdf=|usr=}}{{30889804}}
{{tp|p=28508457|t=2017. Effects of canagliflozin on cardiovascular risk factors in patients with type 2 diabetes mellitus.|pdf=|usr=}}{{28508457}}
{{tp|p=37441489|t=2023. Reduced Levels of the Antiaging Hormone Klotho are Associated With Increased Aortic Stiffness in Diabetic Kidney Disease.|pdf=|usr=}}{{37441489}}
{{tp|p=36837924|t=2023. Hypomagnesemia as a Risk Factor and Accelerator for Vascular Aging in Diabetes Mellitus and Chronic Kidney Disease.|pdf=|usr=}}{{36837924}}
{{tp|p=36185705|t=2022. Sodium-Glucose Cotransporter 2 Inhibitors and Management of Refractory Hypomagnesemia Without Overt Urinary Magnesium Wasting: A Report of 2 Cases.|pdf=|usr=}}{{36185705}}
{{tp|p=35565682|t=2022. The Role of Magnesium in the Pathogenesis of Metabolic Disorders.|pdf=|usr=}}{{35565682}}
{{tp|p=35277073|t=2022. Magnesium in Type 2 Diabetes Mellitus, Obesity, and Metabolic Syndrome.|pdf=|usr=}}{{35277073}}
{{tp|p=34836340|t=2021. Effect of Dapagliflozin and Magnesium Supplementation on Renal Magnesium Handling and Magnesium Homeostasis in Metabolic Syndrome.|pdf=|usr=}}{{34836340}}
{{tp|p=31446746|t=2019. Transient Receptor Potential Channels and Metabolism.|pdf=|usr=}}{{31446746}}
{{tp|p=25733456|t=2015. Genetic variations in magnesium-related ion channels may affect diabetes risk among African American and Hispanic American women.|pdf=|usr=}}{{25733456}}
{{tp|p=23343670|t=2013. Higher magnesium intake is associated with lower fasting glucose and insulin, with no evidence of interaction with select genetic loci, in a meta-analysis of 15 CHARGE Consortium Studies.|pdf=|usr=}}{{23343670}}
{{tp|p=33499378|t=2021. Magnesium in Obesity, Metabolic Syndrome, and Type 2 Diabetes.|pdf=|usr=}}{{33499378}}
{{tp|p=33447354|t=2020. Hypomagnesemia in persons with type 1 diabetes: associations with clinical parameters and oxidative stress.|pdf=|usr=}}{{33447354}}
{{tp|p=33396318|t=2020. Low Dietary Magnesium and Overweight/Obesity in a Mediterranean Population: A Detrimental Synergy for the Development of Hypertension. The SUN Project.|pdf=|usr=}}{{33396318}}
{{tp|p=30742025|t=2019. Diabetes-induced hypomagnesemia is not modulated by metformin treatment in mice.|pdf=|usr=}}{{30742025}}
{{tp|p=24322525|t=2013. Dietary magnesium and genetic interactions in diabetes and related risk factors: a brief overview of current knowledge.|pdf=|usr=}}{{24322525}}
{{tp|p=37908255|t=2023. Improvement in Serum Magnesium Levels With Sodium-Glucose Cotransporter 2 Inhibitors.|pdf=|usr=}}{{37908255}}
{{tp|p=36684386|t=2023. Association of vitamin D and magnesium with insulin sensitivity and their influence on glycemic control.|pdf=|usr=}}{{36684386}}
{{tp|p=31768494|t=2019. Mineral and Electrolyte Disorders With SGLT2i Therapy.|pdf=|usr=}}{{31768494}}
{{ttp|p=30717286|t=2019. Lower Plasma Magnesium, Measured by Nuclear Magnetic Resonance Spectroscopy, is Associated with Increased Risk of Developing Type 2 Diabetes Mellitus in Women: Results from a Dutch Prospective Cohort Study.|pdf=|usr=}}{{30717286}}
{{tp|p=26265998|t=2015. Epigenetic profiles of pre-diabetes transitioning to type 2 diabetes and nephropathy.|pdf=|usr=}}{{26265998}}
{{tp|p=24936262|t=2014. Canagliflozin-current status in the treatment of type 2 diabetes mellitus with focus on clinical trial data.|pdf=|usr=}}{{24936262}}